Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Founder, Chairman, Chief Executive Officer & President Lori Englebert - Executive Vice President of Commercial & Business Development Nick Pizzie - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Yatin Suneja - Guggenheim Partners Jason Gerberry - Bank of America Joseph Thome - Cowen Graig Suvannavejh - Mizuho Securities Chris Howerton - Jefferies Matt Kaplan - Ladenburg Thalmann Myles Minter - William Blair David Hoang - SMBC Operator Good morning, and welcome to the Axsome Therapeutics Conference Call. I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics.

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2022 Results - Earnings Call Transcript

Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates

Axcelis Technologies

Global Blood Therapeutics

GoPro

Health Catalyst Inc

Skillz

Veru

Small-cap growth stocks with 1,000% upside potential is our topic for today. They are usually young companies with a market capitalization (cap) between $300 million and $2 billion.

7 Small-Cap Growth Stocks With 1,000% Upside Potential

Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More importantly, the firm indicated its upcoming labeling discussion for AXS05 with the FDA.

Axsome: Breaking Bearish Trend

Maravai LifeSciences Holdings

Novocure

Each of these stocks is ready for a rebound.

3 Beaten-Down Stocks That Could Soar in the Second Half of 2022

Altimmune

Amylyx Pharmaceuticals

Arcutis Biotherapeutics

bluebird bio

Heron Therapeutics

Intercept Pharma

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on InvestorPlace.

7 Biotech Stocks to Buy for Q3

Immunocore Holdings

Takeda Pharmaceutical

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

What's Winning in 2022? 3 Stocks That Are Doing Fine

Los Angeles, California--(Newsfile Corp. - July 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive...

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , July 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws. Class Period: December 30, 2019 to April 22, 2022 Lead Plaintiff Deadline: July 12, 2022 No obligation or cost to you.

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

NEW YORK , July 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Axsome securities between December 30, 2019 and April 22, 2022, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

New York, New York--(Newsfile Corp. - July 11, 2022) - Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.The lawsuit on behalf of Axsome investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain Axsome Therapeutics, Inc. securities between December 30, 2019 and April 22, 2022. Follow...

AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) securities between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 5, 2020, Axsome released its third quarter

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

New York, New York--(Newsfile Corp. - July 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AXSM FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

Los Angeles, California--(Newsfile Corp. - July 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive...

DEADLINE TOMORROW ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , July 11, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 30, 2019 and April 22, 2022. If you suffered a loss on your investment in Axsome, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022

Los Angeles, California--(Newsfile Corp. - July 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , July 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=29602&from=4 The lawsuit seeks to recover losses for shareholders who purchased Axsome between December 30, 2019 and April 22, 2022.

AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022

Los Angeles, California--(Newsfile Corp. - July 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive...

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , July 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc.. Shareholders who purchased shares of AXSM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 12, 2022 - (NASDAQ: AXSM)

Shareholders with $500,000 losses or more are encouraged to contact the firm.   LOS ANGELES , July 5, 2022 /PRNewswire/ -- The Law Offices of Frank R.

AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit

These stocks appear to have good chances of delivering solid gains by year-end.

3 Growth Stocks That Could Make You Richer in the Second Half of 2022

New York, New York--(Newsfile Corp. - July 3, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 22-cv-03925, is on behalf of a class consisting of all persons and entities other than Defendants that...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

Adaptimmune Therapeutics

G1 Therapeutics

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

AXS-05 labeling discussions with the FDA imply imminent approval. Next 12-18 months will see Axsome transform into a significant commercial neuroscience biotech.

News for Axsome Therapeutics Stock (AXSM)